Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 121

New Drug Slashes Dangerous Blood Fats by Nearly 40% in First Human Trial

When we eat, the body turns surplus calories into molecules called “triglycerides”, especially when those calories come from carbs, sugar, fats, and alcohol. Triglycerides are a type of fat or “lipid”, and the body stores them in fat cells to use as fuel between meals.

However, too much of this fat can become harmful. High triglyceride levels can lead to “hypertriglyceridemia” (“excess triglycerides in the blood”), a condition tied to a much higher risk of heart disease, stroke, and pancreatitis. That is why people are widely encouraged to support healthy triglyceride levels through diet and exercise, while more severe cases may require medication.

Scientists Uncover Potential “Two-in-One” Treatment for Diabetes and Heart Disease

Earlier work linked the experimental drug ‘IC7Fc’ to improvements in type 2 diabetes, and new research now points to a possible role in cardiovascular health as well. Scientists report that the compound may lower the risk of heart disease by reducing harmful cholesterol in the bloodstream and calming inflammatory activity that damages blood vessels over time.

The findings come from a preclinical study published in Science Advances, led by researchers at Leiden University Medical Centre in the Netherlands in collaboration with Monash University and other international partners.

In experiments involving mice genetically predisposed to heart disease, treatment with IC7Fc led to clear reductions in blood fat (triglycerides) and cholesterol, markers closely linked to the development of cardiovascular complications.

Easy-to-use tool can identify high- and low-risk metastatic prostate cancer patients earlier

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment intensification can meaningfully improve survival for patients with aggressive disease.

“Early decline in prostate-specific antigen (PSA) to very low levels is one of the strongest predictors of long-term survival in metastatic prostate cancer. However, clinicians currently have to wait up to six months after starting therapy to see whether a patient achieves this favorable response. For patients who do not respond well, this delay may allow the cancer to progress and become more resistant to treatment,” said Soumyajit Roy, MD, a radiation oncologist at UH Seidman Cancer Center and first author of the study.

Because existing clinical risk stratification tools—such as disease volume or metastatic burden—are relatively imprecise, there has been an unmet need for a reliable, easy-to-use tool that can risk stratify patients earlier, before that critical six-month window closes. Researchers wanted to determine whether it is possible to predict early treatment response at the time of diagnosis for men with metastatic hormone-sensitive prostate cancer (mHSPC) who are treated with modern androgen receptor pathway inhibitors (ARPIs), which are now standard of care worldwide.

Scientists Discover a New “Cleanup Hub” Inside the Human Brain

How does the brain clear away waste? This task is handled by the brain’s lymphatic drainage system, and attempts to understand how it operates have driven major advances in brain imaging.

A new study published in iScience by researchers at the Medical University of South Carolina reports the first human evidence of a previously unrecognized center of lymphatic drainage in the brain, the middle meningeal artery (MMA).

Using a NASA collaboration that gave them access to real-time MRI tools originally designed to study how spaceflight alters fluid movement in the brain, the MUSC team, led by Onder Albayram, Ph.D., followed the movement of cerebrospinal and interstitial fluids along the MMA in five healthy volunteers over six hours. Their observations showed that cerebrospinal fluid moved slowly and passively, a pattern consistent with lymphatic drainage rather than blood circulation, which would be faster and more pulsatile.

Burden of Central Nervous System Cancer in the United States

While incidence rates for central nervous system cancer remained stable from 1990 to 2021, both mortality and disability-adjusted life-years (DALYs) declined. Disparities by geography, age, sex, and sociodemographic status highlight needs for targeted health policy reforms and resource redistribution.

Findings In this cross-sectional study, analysis of the Global Burden of Disease Study 2021 data on US CNS cancers revealed that although the incidence rate remained relatively stable, both disability-adjusted life-years and mortality rates declined. However, substantial disparities persisted across geographical location, age, sex, and sociodemographic profile.

Meaning The persistent disparity in CNS cancer burden highlights the urgent need to reevaluate public health policies and redistribute health care resources to better support marginalized and underserved populations.

Contaminating plasmid sequences and disrupted vector genomes in the liver following adeno-associated virus gene therapy

A valuable paper examining the presence of AAV manufacturing contaminants in a human patient’s liver. These results will hopefully be leveraged for improving the safety of gene therapies in the future.

Analyses of liver biopsies from a child with spinal muscular atrophy treated with adeno-associated virus gene therapy who developed hepatitis reveal contaminating manufacturing plasmids and disrupted vector genomes, possibly resulting from recombination events.

Widespread liver dysfunction in Down syndrome

Patients with detectable virus-specific T cells before checkpoint inhibitor therapy in PML demonstrated better survival rates and functional recovery than those without.

Question Are pretreatment JC virus-and/or BK virus-specific T cells in the blood associated with the efficacy of immune checkpoint inhibitors (ICIs) in progressive multifocal leukoencephalopathy (PML)?

Findings In this cohort study of 111 patients with PML treated with ICIs, those with detectable virus-specific T cells (n = 21) had significantly higher response rates and longer survival than both T cell–negative patients (n = 22) and those with unknown status (n = 68).

Carotid Artery Stenosis—Impactful Bias in Ischemic Stroke Classification

💬 Editorial: Stroke risk classification that relies solely on carotid stenosis severity overlooks patients with nonobstructive but high-risk carotid plaques, underestimating the true contribution of carotid disease to ischemic stroke.

Recent European Society of Cardiology guidelines and Carotid Plaque–RADS offer improved risk stratification by accounting for plaque features, with evidence showing significant gains in predictive accuracy.

This Viewpoint argues that risk classification in ischemic stroke should be expanded beyond stenosis severity to encompass other complementary features, such as plaque morphology, composition, and inflammation.

Stress-reduction molecule has potential to treat aging and metabolic disorders

University of Queensland researchers say the discovery of a new stress reduction role for a naturally occurring molecule in the body could lead to new drugs and treatment for metabolic disorders and aging.

Professor Steven Zuryn, a molecular geneticist from UQ’s Queensland Brain Institute, was part of a team that found that very small RNA molecules, called microRNAs, bind to genes and prevent them from being over-activated.

MicroRNAs were discovered in C. elegans about 30 years ago and have since been shown to be important in human health and disease. This initial discovery led to the 2024 Nobel Prize in Physiology or Medicine.

/* */